Perspectives, analysis, and updates from the Access Bridge team — tracking what matters in HIV prevention access, policy, and the path to equitable scale-up.
The first edition of Bridge Insights: putting women and young people at the centre of PrEP choice, supporting countries with LEN, and lessons from AIDS 2026.
South Africa became the 9th African country to introduce lenacapavir for HIV prevention. AVAC, APHA, and Access Bridge welcomed increased Global Fund commitments while calling for bolder action to turn today's announcement into real-world impact.
Reflections from the International Conference on HIV Treatment, Pathogenesis, and Prevention Research in Dar es Salaam — with key takeaways from AVAC's Grace Kumwenda and Access Bridge's Wawira Nyagah.
Six-monthly injectable lenacapavir is scaling faster than any previous PrEP product — eight African countries delivering, 15 more to follow. The momentum is extraordinary. So is the access challenge.